Methods and compositions for the adar-mediated editing of methyl-cpg binding protein 2 (mecp2)
AssigneeKorro Bio, Inc.
InventorsMatthew Jarpe, Mallikarjuna Reddy Putta, Andrew Fraley
Life of this patent
Estimating the term…
Abstract
The present invention relates to methods and compositions for editing a MECP2 polynucleotide, e.g., a MECP2 polynucleotide comprising a SNP associated with Rett syndrome. The invention also relates to methods and compositions for treating or preventing Rett syndrome in a subject.
Claims28
A method of editing a MECP2 polynucleotide comprising a single nucleotide polymorphism (SNP) associated with Rett syndrome, the method comprising contacting the MECP2 polynucleotide with a guide oligonucleotide capable of effecting an adenosine deaminase acting on RNA (ADAR)-mediated adenosine to inosine alteration of the SNP associated with Rett syndrome, thereby editing the MECP2 polynucleotide.
(canceled)
4-9. (canceled)
A method of treating Rett syndrome in a subject in need thereof, the method comprising
- contacting the MECP2 polynucleotide in a cell of the subject with a guide oligonucleotide capable of effecting an adenosine deaminase acting on RNA (ADAR)-mediated adenosine to inosine alteration of the SNP associated with Rett syndrome, thereby treating the subject.
A method of treating Rett syndrome in a subject in need thereof, the method comprising
- contacting the MECP2 polynucleotide in a cell with a guide oligonucleotide capable of effecting an adenosine deaminase acting on RNA (ADAR)-mediated adenosine to inosine alteration of the SNP associated with Rett syndrome, and
- administering the cell to the subject, thereby treating the subject.
12-13. (canceled)
(canceled)
21-27. (canceled)
29-102. (canceled)
104-106. (canceled)
108-128. (canceled)
130-137. (canceled)
139-144. (canceled)
(canceled)
Dependencies are inferred from the claim text.